fosaprepitant: Clinical Trials

6 trials of fosaprepitant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 not yet recruiting, 1 unknown. 6 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 46Completed 3, Not yet recruiting 2, Unknown 1

Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
Fosaprepitant for Injection, Metoclopramide Injection - Nausea and Vomiting, Nausea
Phase 4Not yet recruitingMontefiore Medical Center2122026-12-012026-06-29
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Aprepitant, Palonosetron, Fosaprepitant - Breast Cancer, Chemotherapy-induced Nausea and Vomiting
Phase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine10282023-07-012023-05-03
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone - Chemotherapy-induced Nausea and Vomiting
Phase 4CompletedMerck Sharp & Dohme LLC1032019-09-092025-01-16
PALONOSETRON X FOSAPREPITANT IN PONV
Palonosetron, Fosaprepitant - Nausea and Vomiting, Postoperative
Phase 4UnknownHospital Federal de Bonsucesso1002019-03-022019-03-12
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Fosaprepitant 150 mg - Postoperative Nausea
Phase 4CompletedStanford University112018-01-012022-07-18
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
fosaprepitant, aprepitant, Oral Placebo - Ovarian Cancer, Uterine Cancer
Phase 4CompletedGynecologic Oncology Associates202011-09-012017-03-28

Conditions studied

Vomiting (4)  ·  Postoperative Nausea and Vomiting (2)  ·  Breast Neoplasms (1)  ·  Nausea (1)  ·  Ovarian Neoplasms (1)  ·  Signs and Symptoms, Digestive (1)  ·  Uterine Neoplasms (1)

Sponsors

Gynecologic Oncology Associates (1)  ·  Hospital Federal de Bonsucesso (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Montefiore Medical Center (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Stanford University (1)

Countries

United States (4)  ·  Brazil (1)  ·  China (1)  ·  Greece (1)  ·  Hungary (1)  ·  Lithuania (1)  ·  Netherlands (1)  ·  Peru (1)  ·  Poland (1)  ·  Russia (1)  ·  United Kingdom (1)

Top investigators

Benjamin Friedman, MD (1)  ·  John P Micha, MD (1)  ·  Mark A Burbridge, MD (1)

Results publications

PMID 39655741

NIH funding

2018 (1)